XGN - Exagen issues preliminary testing revenue ahead of ICT chat

Exagen (XGN) moves up 1.98% after the autoimmune-related healthcare services company posts preliminary figures for FQ4 yesterday. Testing revenue to be $10.5-$10.8M (+10% to +13% Y/Y).However, the company holds back its SIMPONI revenue estimate due to the nature of syndicated pharmaceutical data reporting timing.Consensus: Analysts expect Exagen's total revenue to amount $10.10M (-1.12% Y/Y) and Non-GAAP EPS to be -$0.42 (+57.41%) for the quarter.During the quarter, Exagen delivered a total of ~28,600 AVISE CTD tests, with 1,690 ordering healthcare providers, a record number of 635 adopters and a sequential quarterly retention rate of 99% among adopting healthcare providers."Our core testing business delivered record revenue, driven largely by record quarterly volumes for our flagship AVISE CTD test," says President and CEO Ron Rocca. The company will participate in the 2021 ICR Conference on January 14 at 11:30 AM ET.#ICR21

For further details see:

Exagen issues preliminary testing revenue ahead of ICT chat